Bibliography
- Drüeke TB, Locatelli F, Clyne N, Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Eng J Med 2006;335:2071-84
- Singh AK, Szczech L, Tang KL, Correction of anemia with epoetin alfa in chronic kidney disease. N Eng J Med 2006;335:2085-98
- Pfeffer MA, Burdmann EA, Chen CY, TREAT investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32
- Skali H, Parving HH, Parfrey PS, TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 2011;124(25):2903-8
- Del Vecchio L, Locatelli F. Safety issues related to erythropoiesis-stimulating agents used to treate anemia in patients with chronic kidney disease. Exp Opin Drug Saf 2012;11(6):923-32
- Besarab A, Bolton WK, Browne JK, The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90
- Available from: http://www.fda.gov/Drugs/DrugSafety/ucm259639.htm [Last accessed 14 July 2012]
- Valderrábano F, Hörl WH, Jacobs C, Patients and methods. Nephrol Dial Transplant 2000;15(suppl 4):2-7
- Palmer SC, Navaneethan SD, Craig JC, Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153(1):23-33
- Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Inter 2012(Suppl 2)):279-335